AI assistant
Sending…
TuHURA Biosciences, Inc./NV — Director's Dealing 2017
Feb 22, 2017
34026_dirs_2017-02-22_ef356ed4-cb61-46ce-a090-f20fb95cbf91.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DelMar Pharmaceuticals, Inc. (DMPI)
CIK: 0001498382
Period of Report: 2017-02-17
Reporting Person: Praill Scott (CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-17 | Options (Right to Buy) | $4.95 | A | 37400 | Acquired | 2027-02-17 | Common Stock (37400) | Direct |
Footnotes
F1: The options vest in equal monthly installments over three years.
More from TuHURA Biosciences, Inc./NV
Regulatory Filings
2026
May 29
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
Apr 22
Regulatory Filings
2026
Apr 8
Regulatory Filings
2026
Apr 8
Regulatory Filings
2026
Apr 1
Director's Dealing
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2026
Feb 17